Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.44 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18581120 | 1.00 | MAPT (0.52) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL18581490 | 0.93 | KDM4E (0.52) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL29790747 | 0.93 | KDM4E (0.52) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL18581009 | 0.92 | HDAC1 (0.57) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL18581261 | 0.90 | MAPT (0.54) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL29790799 | 0.90 | MAPT (0.54) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL29790715 | 0.90 | MAPT (0.46) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL18581206 | 0.90 | MAPT (0.46) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL18581373 | 0.89 | ALDH1A1 (0.58) | MAPTMEN1LMNAKMT2AHDAC1 | |
| SCHEMBL23356530 | 0.88 | MAPT (0.52) | MAPTMEN1LMNAKMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | Valo Health, LLC | 2023-12-21 | — | — | US | disclosed |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406830-A1 | [6,6] FUSED BICYCLIC HDAC8 INHIBITORS | HDAC8, HDAC3, HDAC2 | MAPT 135/4885MEN1 3243/4885LMNA 558/4885 |
| US-11414392-B2 | [6,6] fused bicyclic HDAC8 inhibitors | HDAC8, HDAC3, HDAC2 | MAPT 135/4885MEN1 3243/4885LMNA 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.